

Pharmacy Formulary Updates for May 2018

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status in May 2018:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Direct Formulary
Makena	MB
Baxdela tablets	T3
Odactra	T3;PA;QL
Vyzulta	T3;ST ^{PA}
Armonair RespiClick	NC;QL
Bonjesta	NC
Firvanq	T3;QL
Tasigna 50 mg	T2;SP;PA
Citranatal capsules	NC
tiagabine 12 & 16 mg tablets	T2
Gabitril 12 & 16 mg tablets	NC
lansoprazole DR ODT	T3;PA (for members older than 12);QL
Prevacid Solutab	NC;QL

Key:

- | | |
|--------------------------------|--|
| MB: Medical Benefit | QL: Quantity Limitation |
| NC: Not covered | SP: Specialty Pharmacy - provided through CVS/specialty |
| NTM: New-to-market | ST: Step Therapy |
| PA: Prior Authorization | |